GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » King International Investment Ltd (HKSE:00928) » Definitions » Cash Conversion Cycle

King International Investment (HKSE:00928) Cash Conversion Cycle : 466.58 (As of Sep. 2023)


View and export this data going back to 2002. Start your Free Trial

What is King International Investment Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

King International Investment's Days Sales Outstanding for the six months ended in Sep. 2023 was 246.83.
King International Investment's Days Inventory for the six months ended in Sep. 2023 was 241.71.
King International Investment's Days Payable for the six months ended in Sep. 2023 was 21.96.
Therefore, King International Investment's Cash Conversion Cycle (CCC) for the six months ended in Sep. 2023 was 466.58.


King International Investment Cash Conversion Cycle Historical Data

The historical data trend for King International Investment's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

King International Investment Cash Conversion Cycle Chart

King International Investment Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 38.89 -3.35 110.10 158.10 109.31

King International Investment Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 119.05 -2,499.95 129.94 115.60 466.58

Competitive Comparison of King International Investment's Cash Conversion Cycle

For the Diagnostics & Research subindustry, King International Investment's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


King International Investment's Cash Conversion Cycle Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, King International Investment's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where King International Investment's Cash Conversion Cycle falls into.



King International Investment Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

King International Investment's Cash Conversion Cycle for the fiscal year that ended in Mar. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=115.4+0.02-6.11
=109.31

King International Investment's Cash Conversion Cycle for the quarter that ended in Sep. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=246.83+241.71-21.96
=466.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


King International Investment  (HKSE:00928) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


King International Investment Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of King International Investment's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


King International Investment (HKSE:00928) Business Description

Traded in Other Exchanges
N/A
Address
18 Harbour Road, Room 6307-08, 63rd Floor, Central Plaza, Wanchai, Hong Kong, HKG
King International Investment Ltd formerly Life Healthcare Group Ltd is an investment holding company. The company's operating segment includes the Healthcare products and services business and Money lending business. It generates maximum revenue from the Healthcare products and services business segment. Geographically, it derives a majority of revenue from PRC. The group is primarily a provider of genetic testing and health data analysis services.

King International Investment (HKSE:00928) Headlines

No Headlines